This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to veliparib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. EAP is also available for other indications where there is reasonable scientific basis for efficacy.
Location: SIMR(Sacramento/Valley Area)
Please contact KirstenBabski email@example.com about Study AbbVie ABT-888View study details on ClinicalTrials.gov
September 10, 2020